BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 11252890)

  • 1. Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.
    Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas R; Medina B; Mohedano N; Fernández M; Martos M; Lozano A; Carrasco E
    Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):44-7. PubMed ID: 11252890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
    Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
    Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
    Passardi A; Massa I; Zoli W; Gianni L; Milandri C; Zumaglini F; Nanni O; Maltoni R; Frassineti GL; Amadori D
    BMC Cancer; 2006 Mar; 6():76. PubMed ID: 16551351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer.
    Conte P; Salvadori B; Donati S; Gennari A; Cetto GL; Molino A; Crino L; Mazzoni F; Galligioni E; Mansutti M
    Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):41-3. PubMed ID: 11252889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
    Murad AM
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):26-32. PubMed ID: 14768402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
    Miller KD; Sisk J; Ansari R; Gize G; Nattam S; Pennington K; Monaco F; Sledge GW
    Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):38-40. PubMed ID: 11252888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer.
    Delfino C; Caccia G; Riva Gonzáles L; Mickiewicz E; Rodger J; Balbiani L; Flores Morales D; Zori Comba A; Brosio C
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):22-5. PubMed ID: 14768401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.
    Demiray M; Kurt E; Evrensel T; Kanat O; Arslan M; Saraydaroglu O; Ercan I; Gonullu G; Gokgoz S; Topal U; Tolunay S; Tasdelen I; Manavoglu O
    Cancer Invest; 2005; 23(5):386-91. PubMed ID: 16193637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
    Iaffaioli RV; Tortoriello A; Santangelo M; Turitto G; Libutti M; Benassai G; Frattolillo A; Ciccarelli PD; De Rosa P; Crovella F; Carbone I; Barbarisi A
    Clin Oncol (R Coll Radiol); 2000; 12(4):251-5. PubMed ID: 11005695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
    Mavroudis D; Malamos N; Alexopoulos A; Kourousis C; Agelaki S; Sarra E; Potamianou A; Kosmas C; Rigatos G; Giannakakis T; Kalbakis K; Apostolaki F; Vlachonicolis J; Kakolyris S; Samonis G; Georgoulias V
    Ann Oncol; 1999 Feb; 10(2):211-5. PubMed ID: 10093691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine and paclitaxel as salvage therapy in metastatic breast cancer.
    Murad AM; Guimarães RC; Aragão BC; Scalabrini'Neto AO; Rodrigues VH; Garcia R
    Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):25-7. PubMed ID: 11252885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
    Yardley DA; Brufsky A; Coleman RE; Conte PF; Cortes J; Glück S; Nabholtz JM; O'Shaughnessy J; Beck RM; Ko A; Renschler MF; Barton D; Harbeck N
    Trials; 2015 Dec; 16():575. PubMed ID: 26673577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
    Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
    Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study.
    El Serafi MM; El Khodary AI; El Zawahry HR; Mansour OM; Gaballa HE
    J Egypt Natl Canc Inst; 2006 Sep; 18(3):209-15. PubMed ID: 17671530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
    Hu XC; Zhang J; Xu BH; Cai L; Ragaz J; Wang ZH; Wang BY; Teng YE; Tong ZS; Pan YY; Yin YM; Wu CP; Jiang ZF; Wang XJ; Lou GY; Liu DG; Feng JF; Luo JF; Sun K; Gu YJ; Wu J; Shao ZM
    Lancet Oncol; 2015 Apr; 16(4):436-46. PubMed ID: 25795409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
    Kornek GV; Haider K; Kwasny W; Raderer M; Schüll B; Payrits T; Depisch D; Kovats E; Lang F; Scheithauer W
    Clin Cancer Res; 2002 May; 8(5):1051-6. PubMed ID: 12006518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
    Rivera E; Valero V; Arun B; Royce M; Adinin R; Hoelzer K; Walters R; Wade JL; Pusztai L; Hortobagyi GN
    J Clin Oncol; 2003 Sep; 21(17):3249-54. PubMed ID: 12947059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
    Sledge GW
    Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):33-5. PubMed ID: 14768403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer.
    Georgoulias VA
    Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):18-24. PubMed ID: 11252884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.